Topic: inflammatory diseases
Viela's inebilizumab reduced attacks from the rare autoimmune disease neuromyelitis optica spectrum disorders by 73%.
Viela Bio came to be when AstraZeneca hived off a clutch of programs in inflammatory and autoimmune diseases.
Novartis is picking up one clinical-stage and two preclinical NLRP3 antagonist programs in its acquisition of IFM Tre.
Horizon Pharma’s inflammatory eye drug teprotumumab reduced eye bulging in a phase 3 study, meeting its primary endpoint.
IFM Therapeutics is unveiling its second subsidiary, IFM Due, which will target the cGAS/STING pathway to treat inflammatory and autoimmune disease.
Inflazome has brought on Thomas Jung, M.D., Ph.D., to be its new chief medical officer and lead clinical development of its NLRP3 inhibitors.
Genentech acquired Jecure Therapeutics and its stable of NLRP3 inhibitors for an undisclosed amount.
The agreement covers small molecules designed to treat multiple neurodegenerative and systemic inflammatory diseases.
Newly formed British biotech Sitryx will use the money and its relationship with GSK to move immunometabolism assets toward human testing.
Jared Gollob, M.D., is joining Kymera Therapeutics, a startup focused on protein degradation.